Author: it
Nov2017
CTAD 2017 (Boston, USA | 1-4 Nov)
Dr Mohammad Afshar (Ariana CEO) is presenting on the analysis of Phase 2a trial results using Ariana’s KEM® artificial intelligence platform at CTAD 2017 (10th Clinical Trials on Alzheimer’s Disease) in Boston, USA on 4 November. LB18 – Clinical Pharmacokinetics and Pharmacodynamics Characterization of ANAVEX™2-73 for Designing a Phase 2/3 Study in Mild-to-Moderate Alzheimer’s Disease […]
Oct2017
Anavex incorporating Ariana’s KEM® AI platform in Alzheimer’s precision medicine approach
Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate Alzheimer’s Disease PatientsANAVEX2-73 demonstrates desirable PK/PD properties, describing the relationship between drug concentration and the effect observed.Anavex is incorporating advanced Artificial Intelligence platform for the analysis of Phase 2a results with the aim to increase the chances of success […]
Jun2017
WIN 2017 (Paris | Jun 26-27)
Meet the Ariana team of Dr Mohammad Afshar (CEO) and Dr Mariana Kuras (CTO) at the WIN 2017 Symposium this week. The conference program will elaborate the theme ‘Expediting Global Innovation in Precision Cancer Medicine’ and is the place to be to learn about the latest in cancer research from leading practioners.
May2017
Ariana Pharma finalist in EU eHealth 2017 with Onco KEM
Ariana Pharma were finalists in the Champions Category of the EU eHealth 2017 Competition with its clinical decision support system for oncologists, Onco KEM. Our solution: The right drug to the right patient with Onco KEM®, a novel decision support system helping oncologists to personalize cancer treatments according to the molecular profile of each patient. […]
May2017
API 2017 (Panama | May 16-20)
Two posters highlighting the use of Ariana’s Real World Evidence (RWE) platform for large scale data mining of healthcare records are to be presented at API 2017 (Asociacion Panamericana de Infectologia) – XVIII Congresso Panamericano de Infectologia, Panama, 16-20 May 2017. The studies focus on retrospective analyses of risk factors for dengue mortality in hospitalized […]
May2017
Broadening the reach of Precision Medicine beyond DNA
Initial results of Onco KEM and the WINTHER trial were presented at TAT 2017: 15th International Congress on Targeted Anticancer Therapies, 6-8 Mar 2017, Paris, France. The study demonstrates that the innovative Onco KEM transcriptomic-based decision support system fills a gap left by traditional DNA based targeted therapy, enabling more patients to reach a larger […]
Nov2016
Ariana to present on Combination Therapy in Melanoma with Harvard Medical School (Paris | Nov 29 – Dec 2nd)
Dr Parmentier will present a poster “Combination Therapy in Melanoma: finding biomarkers of synergistic associations using Large Scale Drug Combination Screening and integrated Omics Data Analysis” at the Institut Pasteur International Network Scientific Symposium in Paris on November 30th. The poster showcases the results of a collaborative study between Ariana and the Massachusetts General […]
Nov2016
Ariana to showcase Real World Evidence platform at ASTMH 2016 (Atlanta, USA | Nov 13-17)
Dr David Morley, VP Computational Technology, will be co-presenting a poster at the 65th Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH 2016) in Atlanta, USA. Poster 212 “Management of dengue hospitalizations in Brazil during and outside epidemic periods: Insights from Data Mining” is a joint presentation with Sanofi Pasteur and […]
Oct2016
Anavex and Ariana Pharma Collaborate to Accelerate Timelines and Improve Efficiency of Alzheimer’s and Parkinson’s Clinical Development Programs
NEW YORK, NY – October 5, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced a collaboration with Ariana Pharma […]
Sep2016
Ariana Pharma (Paris, Boston) and ValiSeek (London) to collaborate on Phase II Non-small Cell Lung Cancer treatment
Ariana’s advanced data analytics, using its KEM® decision support platform, will help ValiSeek boost success outlook. Ariana® Pharma, a leading digital health Company focused on developing advanced personalized therapeutic decision support systems and a provider of decision support tools and services to accelerate drug development, announces today that it has won a significant contract of […]